Macrophage anti-tumour response in a microfluidic chip
2022
Radboud University Medical Center, Nijmegen, Netherlands
This study reports a microfluidic tumour-on-a-chip system combining macrophages and tumour cells in a 3D collagen matrix. For proof of concept, the platform was utilized to obtain novel insights for a promising therapeutic combination of an IgA antibody against epidermal growth factor receptor (EGFR) with a CD47-blocking fusion protein acting as an innate immune checkpoint inhibitor. Employing the chip assay, it was shown that the combination of anti-EGFR IgA and a CD47 checkpoint inhibitor synergistically activate macrophage phagocytic function to specifically kill cancer cells. The model is especially useful in immuno-oncology, as there are substantial interspecies differences in how cells of the immune system operate. Thus, the developed model allows a human-centred investigation of novel immunotherapeutic approaches.
Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model
Wouter P.R. Verdurmen
Added on: 04-28-2022
[1] https://www.sciencedirect.com/science/article/pii/S2666102022000052
